The Cancer Drugs Market: 2023 – 2033 – Opportunities, Challenges, Strategies & Forecasts

Release Date: October 2023
Number of Pages: 372
Number of Tables and Figures: 57

Synopsis: Acknowledged as a prominent global health concern, cancer represents a spectrum of illnesses distinguished by uncontrolled cellular proliferation, culminating in the development of malignant tumors capable of infiltrating adjacent tissues which ultimately impair normal functions. Approximately 19.5 million new cases globally each year are diagnosed. However, several immunotherapy and targeted treatments have significantly improved patient outcomes and survival rates.

The market is ripe for future growth with several targeted therapies in late-stage development, such as PD-1/PD-L1 inhibitors and ADCs, as well as combination therapies countering tumor resistance. An innovative landscape awaits cancer treatment, driven by advancements in cell therapies like CAR-T and TCR for solid tumors, along with the emergence of "off-the-shelf" cellular therapy options.
As new drugs continue to revitalize the cancer treatment ecosystem, we expect the cancer drugs market to grow at a CAGR of 12.1% between 2023 and 2028, eventually accounting for nearly $369.5 Billion in revenue by 2028.

The “Cancer Drugs Market: 2023 – 2033 – Opportunities, Challenges, Strategies & Forecasts” report presents an in-depth assessment of the cancer drugs ecosystem including treatment options, key trends, market drivers, challenges, investment potential, leading therapies, drug development pipeline, opportunities, future roadmap, value chain, ecosystem player profiles and strategies. The report also presents market size forecasts for cancer drugs from 2023 through to 2033. The forecasts are segmented for 2 therapeutic pathways, 11 therapeutic categories, 5 regions and 25 leading countries.

The report comes with an associated Excel datasheet suite covering quantitative data from all numeric forecasts presented in the report and the cancer drug development pipeline data.
For a Sample and Table of Contents please contact [email protected]

Pricing: The report is available for the following price: 

Single User License: USD 3,000

Company Wide License (Single Site): USD 4,500

Company Wide License (Global Site): USD 7,500

Key Findings:
The report has the following key findings:

  • As new drugs continue to revitalize the cancer treatment ecosystem, we expect the cancer drugs market to grow at a CAGR of 12.1% between 2023 and 2028, eventually accounting for nearly $369.5 Billion in revenue by 2028.
  • The market is ripe for future growth with several targeted therapies in late-stage development, such as PD-1/PD-L1 inhibitors, as well as antibody-drug conjugates (ADCs) and a number of combination therapies.
  • Another key area of focus for future drug development is CAR-T (Chimeric Antigen Receptor T-Cell) therapy, which involves engineering immune cells to recognize and attack their tumors.
  • The industry continues to witness consolidation in the form of both acquisitions and mergers. Strategic collaborations are also rife in the ecosystem. For example, Merck partnered with China’s Kelun-Biotech, investing heavily in ADCs while Roche is investing in Poseida Therapeutics' portfolio that target hematologic malignancies.

Topics Covered:
The report covers the following topics:

  • Cancer drugs ecosystem
  • Market drivers and barriers
  • Types of cancer, treatment options and key trends
  • Analysis of key drug classes and leading cancer drugs
  • Future drug development pipeline
  • Industry roadmap and value chain
  • Profiles and strategies of 92 leading ecosystem players, including cancer drug developers
  • Strategic recommendations for ecosystem players
  • Market analysis and forecasts from 2023 till 2033

Historical Revenue & Forecast Segmentation:
Market forecasts are provided for each of the following submarkets and their subcategories:
  • Therapeutic Pathways
    • Immuno-Oncology & Targeted Therapies
    • Cytotoxic & Hormonal Therapies
  • Therapeutic Categories
    • Blood Cancer
    • Breast Cancer
    • Colorectal Cancer
    • Gastric Cancer
    • Lung Cancer
    • Ovarian Cancer
    • Pancreatic Cancer
    • Prostate Cancer
    • Renal Cancer
    • Skin Cancer
    • Other Cancers
  • Regional Markets
    • Asia Pacific
    • Europe
    • Middle East & Africa
    • North America
    • Latin & Central America
  • Country Markets
    • Brazil
    • Canada
    • China
    • Egypt
    • France
    • Germany
    • Greece
    • India
    • Israel
    • Italy
    • Japan
    • Mexico
    • Netherlands
    • Poland
    • Portugal
    • Russia
    • Saudi Arabia
    • South Africa
    • South Korea
    • Spain
    • Switzerland
    • Taiwan
    • Turkey
    • UK
    • USA

Key Questions Answered:
The report provides answers to the following key questions:
​
  • How big is the cancer drugs opportunity?
  • What trends, challenges and barriers are influencing its growth?
  • How is the ecosystem evolving by segment and region?
  • What will the market size be in 2023 and at what rate will it grow?
  • Which countries and submarkets will see the highest percentage of growth?
  • What are the prospects of biosimilar drugs in oncology?
  • How big is the market for immuno-oncology & targeted therapies?
  • Who are the key market players and what are their strategies?
  • How will patent expirations of innovator drugs impact the market?
  • What strategies should cancer drug manufacturers adopt to remain competitive?

List of Companies Mentioned:
The following companies and organizations have been reviewed, discussed or mentioned in the report:

AB Science
AbbVie
AbClon
Ability Pharmaceuticals
ABL Bio
Acceleron Pharma
Acrivon Therapeutics
Active Biotech
Adaptimmune Therapeutics
Adimab
Aduro Biotech
Agenus
Akeso Biopharma
Alaunos Therapeutics
Alphamab
Amgen
Amneal Pharmaceuticals
Amplia Therapeutics
Arcellx
Arcus Biosciences
ARIAD Pharmaceuticals
Array BioPharma
Arvinas
Ascentage Pharma
AskGene Pharma
Astellas Pharma
AstraZeneca
AvenCell Europe
Avid Bioservices
Azanta (Norgine)
Baxalta
Baxter International
Bayer
Bayer Healthcare
BeiGene
Bellicum Pharmaceuticals
Biocad
Biokine Therapeutics
BioLineRx
BioLite Inc.
Biomea Fusion
Biomunex Pharmaceuticals
Bionovo
BioNTech
BMS (Bristol-Myers Squibb)
Boehringer Ingelheim
CanBas
Candel Therapeutics
CARsgen Therapeutics
Celgene
Celgene Corporation
Celldex Therapeutics
Cellectics
Checkpoint Therapeutics
Chia Tai Tianqing Pharmaceutical Group
Cinnagen
Clovis Oncology
Cornerstone Pharmaceuticals
CSPC ZhongQi Pharmaceutical Technology
CTI BioPharma
CureTech
Daiichi Sankyo Company
Dainippon Sumitomo
Denovo Biopharma 
DFB Soria
Dialectic Therapeutics
Dr. Reddy's Laboratories
Duke Science & Technology (DST)
Eagle Pharmaceuticals
ECOG-ACRIN Cancer Research Group
EirGenix
Eisai
Eli Lilly & Company
Emcure Pharmaceuticals 
ENB Therapeutics
EnhancedBio
Epizyme
Eternity Bioscience
Exelixis
FibroGen
FKD Therapies
Galera Therapeutics
Gamida Cell
Genentech
Genmab
Geron Corporation
Gilead Sciences
Globeimmune
Golden Biotechnology Corporation
GSK (GlaxoSmithKline)
Hangzhou Neoantigen Therapeutics
HCW Biologics
Helix BioPharma
Helsinn
Henlix Biotech
HLB
Hutchmed
Immatics
Immix Biopharma
Immune Pharmaceuticals
ImmunityBio
Immunocore
ImmunoGen
Immunomedics
Imunon
Incyte Corporation
Infinity Pharmaceuticals
Innate Pharma
Innovation Pharmaceuticals
iOnctura
Ipsen
iTeos Therapeutics
J&J Innovative Medicine
J&J MedTech
Janssen
Jazz Pharmaceuticals
Jiangsu Hengrui Medicine
Johnson & Johnson
Juno Therapeutics
Karyopharm Therapeutics
Kelun-Biotech
Kintara Therapeutics
Kite Pharma
Kronos Bio
Kura Oncology
Kuur Therapeutics
Light Chain Bioscience
Lineage Cell Therapeutics
LIPAC Oncology
Lisata Therapeutics
Lokon Pharma
Loxo Oncology
Lumicell
Mabpharm
MabVax Therapeutics
MacroGenics
Mark Cuban Cost Plus Drug Company
Massachusetts General Hospital
Massachusetts Institute of Technology (MIT)
Medivation
MEI Pharma
Memorial Sloan Kettering Cancer Center (MSK)
Merck & Co.
Merck KGaA
Merrimack Pharmaceuticals
Merus
MetiMedi Pharmaceuticals
Mirati Therapeutics
Model Medicines
MorphoSys
Mustang Bio
Mylan
NanOlogy
NanoString Technologies
National Cancer Institute (NCI)
National Institutes of Health (NIH)
Nektar Therapeutics
Nelum
NewLink Genetics
NGM Biopharmaceuticals
Novartis
Novartis Oncology
NovImmune SA
Nuvation Bio
Octimet Oncology
Oncoheroes Biosciences
Oncolytics Biotech
OncoMed Pharmaceuticals
Oncopeptides
OncoSec Medical
OncoTherapy Science 
Oncothyreon
Onxeo
Onyx Pharmaceuticals
Orbus Therapeutics
Orion Pharma
Otsuka Holdings
Panbela Therapeutics
Peregrine Pharmaceuticals
Pfizer
PharmaMar
Photocure
Plexxikon
Poseida Therapeutics' 
Precision BioSciences
Prestige BioPharma
Provectus Biopharmaceuticals
Puma Biotechnology
QED Therapeutics (BridgeBio Pharma)
Qilu pharmaceutical
Qualigen Therapeutics
Radius Health
Redx Pharma
Regeneron Pharmaceuticals
RemeGen
Rise Biopharmaceuticals
Roche
R-Pharm
Sanofi
Scandion Oncology
Seagen
Secura Bio
SELLAS Life Sciences Group
Sentinel Oncology
Servier
Sesen Bio
Shandong Boan Biotechnology
Shanghai Hengrui Pharmaceutical
Shanghai Henlius Biotech
Shanghai Junshi Biosciences
Shanghai Unicar-Therapy Bio-medicine Technology
Silenseed
Sobi
SOM Biotech
Sony Corporation 
St. Jude Research
Starton Therapeutics
Sumitomo Dainippon Pharma
Sun Pharmaceutical Industries
Sunesis Pharmaceuticals
Suzhou NeuPharma
Symphogen
Syndax Pharmaceuticals
SynerGene Therapeutics
Taiho Pharmaceutical
Takeda
Takeda Oncology
Takeda Pharmaceutical Company
Tarveda Therapeutics
Tavanta Therapeutics
Tesaro
Teva Pharmaceutical Industries
TG Therapeutics
The Mount Sinai Health System
The National Health Service (NHS)
The National Institute for Health and Care Excellence (NICE)
Threshold Pharmaceuticals
Timmune Biotech
TME Pharma
Turning Point Therapeutics
U.S. Food and Drug Administration (FDA)
U-Cell Therapeutics
United Therapeutics
University of California
University of Pennsylvania
UroGen Pharma
Vaccinogen
VBL therapeutics
Verastem Oncology
X4 Pharmaceuticals
XBiotech
Xuanzhu Biopharmaceutical
Yantai Rongchang Pharmaceutical
Zenopharm
Zymeworks